Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label maintenance erlotinib after chemoradiotherapy for stage III non-small cell lung cancer
2005-004604-36Phase 2Active
- Sponsor
- Grupo Gallego de Cáncer de Pulmón
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Grupo Gallego de Cáncer de Pulmón. Primary endpoint: Progression-free rate at 6 months. Started Nov 2005; status: active.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-004604-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004604-36.